HSBC Holdings
PCVX icon

HSBC Holdings’s Vaxcyte PCVX Stock Holding History

HSBC Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Sell
3,992
-3,806
-49% -$207K ﹤0.01% 2557
2025
Q4 		$363K Sell
7,798
-42,827
-85% -$1.92M ﹤0.01% 2443
2025
Q3 		$1.81M Buy
50,625
+31,409
+163% +$1.04M ﹤0.01% 1541
2025
Q2 		$628K Buy
19,216
+755
+4% +$24.8K ﹤0.01% 2038
2025
Q1 		$675K Buy
18,461
+552
+3% +$44.1K ﹤0.01% 1931
2024
Q4 		$1.45M Buy
17,909
+4,443
+33% +$441K ﹤0.01% 1614
2024
Q3 		$1.53M Sell
13,466
-480
-3% -$43.3K ﹤0.01% 1528
2024
Q2 		$1.05M Buy
+13,946
New +$949K ﹤0.01% 1664

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's PCVX Position: Q1 2026 in Review

HSBC Holdings reduced its Vaxcyte (PCVX) stake by 49% in Q1 2026, selling an estimated $207K and leaving 3,992 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

HSBC Holdings first reported a position in PCVX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.81M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • HSBC Holdings held 3,992 shares of Vaxcyte worth $232K as of Q1 2026.
  • HSBC Holdings sold 3,806 Vaxcyte shares in Q1 2026, an estimated $207K.
  • Vaxcyte made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2557 holding.
  • HSBC Holdings first reported a position in Vaxcyte in Q2 2024 and has held it in 8 quarters since.
  • HSBC Holdings's Vaxcyte position peaked at $1.81M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.